Life sciences companies eventually reach the moment when planning shifts from R&D burn to revenue generation.

In this episode of Planning Pulse, Matt Harvison and Thomas Trammel explore how biotech and pharma organizations can model revenue in Workday Adaptive Planning, from subscriptions and licensing to unit-based product sales.

They walk through practical forecasting models that connect revenue planning to the income statement, balance sheet, and cash flow, helping organizations protect cash runway while scaling toward commercialization.

This episode also marks the final release of Planning Pulse as a standalone podcast. Going forward, the segment will continue inside the expanded Workday Reimagined podcast.